| Drug Name |
Deferiprone |
| Drug ID |
BADD_D00595 |
| Description |
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. |
| Indications and Usage |
Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload. |
| Marketing Status |
approved |
| ATC Code |
V03AC02 |
| DrugBank ID |
DB08826
|
| KEGG ID |
D07416
|
| MeSH ID |
D000077543
|
| PubChem ID |
2972
|
| TTD Drug ID |
D0N0OU
|
| NDC Product Code |
17349-0023; 10122-103; 0054-0711; 10122-100; 51672-4196; 10122-104; 10122-101; 0054-0576; 52609-4502 |
| UNII |
2BTY8KH53L
|
| Synonyms |
Deferiprone | 1,2-Dimethyl-3-hydroxy-4-pyridinone | 1,2 Dimethyl 3 hydroxy 4 pyridinone | DMOHPO | 1,2-Dimethyl-3-hydroxypyrid-4-one | 1,2 Dimethyl 3 hydroxypyrid 4 one | 3-Hydroxy-1,2-dimethyl-4-pyridinone | 3 Hydroxy 1,2 dimethyl 4 pyridinone | HDMPP | 1,2-Dimethyl-3-hydroxypyridin-4-one | 1,2 Dimethyl 3 hydroxypyridin 4 one | Ferriprox |
